Your browser doesn't support javascript.
loading
Rapid Detection of SARS-CoV-2 RNA Using Reverse Transcription Recombinase Polymerase Amplification (RT-RPA) with Lateral Flow for N-Protein Gene and Variant-Specific Deletion-Insertion Mutation in S-Protein Gene.
Malaga, Jose L; Pajuelo, Monica J; Okamoto, Michiko; Tsinda, Emmanuel Kagning; Otani, Kanako; Tsukayama, Pablo; Mascaro, Lucero; Cuicapuza, Diego; Katsumi, Masamichi; Kawamura, Kazuhisa; Nishimura, Hidekazu; Sakagami, Akie; Ueki, Yo; Omiya, Suguru; Okamoto, Satoshi; Nakayama, Asami; Fujimaki, Shin-Ichi; Yu, Chuyao; Azam, Sikandar; Kodama, Eiichi; Dapat, Clyde; Oshitani, Hitoshi; Saito, Mayuko.
Afiliação
  • Malaga JL; Department of Virology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan.
  • Pajuelo MJ; Laboratorio Microbiología Molecular, Laboratorios de Investigación y Desarrollo, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima 15102, Peru.
  • Okamoto M; Department of Virology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan.
  • Tsinda EK; Department of Virology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan.
  • Otani K; Center for Biomedical Innovation, Sinskey Lab, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  • Tsukayama P; National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Mascaro L; Laboratorio de Genómica Microbiana, Universidad Peruana Cayetano Heredia, Lima 15102, Peru.
  • Cuicapuza D; Laboratorio Microbiología Molecular, Laboratorios de Investigación y Desarrollo, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima 15102, Peru.
  • Katsumi M; Laboratorio de Genómica Microbiana, Universidad Peruana Cayetano Heredia, Lima 15102, Peru.
  • Kawamura K; Sendai City Institute of Health, Sendai 984-0002, Japan.
  • Nishimura H; Sendai Shirayuri Women's College, Sendai 981-3107, Japan.
  • Sakagami A; Kawamura Children's Clinic, Sendai 981-0907, Japan.
  • Ueki Y; Virus Research Center, Clinical Research Division, Sendai Medical Center, Sendai 983-8520, Japan.
  • Omiya S; Department of Microbiology, Miyagi Prefectural Institute of Public Health and Environment, Sendai 983-0836, Japan.
  • Okamoto S; Department of Microbiology, Miyagi Prefectural Institute of Public Health and Environment, Sendai 983-0836, Japan.
  • Nakayama A; Virus Research Center, Clinical Research Division, Sendai Medical Center, Sendai 983-8520, Japan.
  • Fujimaki SI; Department of Clinical Laboratory, Tohoku Kosai Hospital, Sendai 980-0803, Japan.
  • Yu C; Department of Laboratory Medicine, Tohoku University Hospital, Sendai 980-8574, Japan.
  • Azam S; Department of Laboratory Medicine, Tohoku University Hospital, Sendai 980-8574, Japan.
  • Kodama E; Department of Virology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan.
  • Dapat C; Department of Virology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan.
  • Oshitani H; International Research Institute of Disaster Science, Tohoku University, Sendai 980-8572, Japan.
  • Saito M; Department of Virology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan.
Viruses ; 15(6)2023 05 26.
Article em En | MEDLINE | ID: mdl-37376555
ABSTRACT
Rapid molecular testing for severe acute respiratory coronavirus 2 (SARS-CoV-2) variants may contribute to the development of public health measures, particularly in resource-limited areas. Reverse transcription recombinase polymerase amplification using a lateral flow assay (RT-RPA-LF) allows rapid RNA detection without thermal cyclers. In this study, we developed two assays to detect SARS-CoV-2 nucleocapsid (N) gene and Omicron BA.1 spike (S) gene-specific deletion-insertion mutations (del211/ins214). Both tests had a detection limit of 10 copies/µL in vitro and the detection time was approximately 35 min from incubation to detection. The sensitivities of SARS-CoV-2 (N) RT-RPA-LF by viral load categories were 100% for clinical samples with high (>9015.7 copies/µL, cycle quantification (Cq) < 25) and moderate (385.5-9015.7 copies/µL, Cq 25-29.9) viral load, 83.3% for low (16.5-385.5 copies/µL, Cq 30-34.9), and 14.3% for very low (<16.5 copies/µL, Cq 35-40). The sensitivities of the Omicron BA.1 (S) RT-RPA-LF were 94.9%, 78%, 23.8%, and 0%, respectively, and the specificity against non-BA.1 SARS-CoV-2-positive samples was 96%. The assays seemed more sensitive than rapid antigen detection in moderate viral load samples. Although implementation in resource-limited settings requires additional improvements, deletion-insertion mutations were successfully detected by the RT-RPA-LF technique.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Transcrição Reversa / COVID-19 Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Revista: Viruses Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Transcrição Reversa / COVID-19 Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Revista: Viruses Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão